|
AXA Meeting Date: APR 26, 2017 Record Date: APR 21, 2017 Meeting Type: ANNUAL/SPECIAL |
Ticker: CS Security ID: F06106102 |
Proposal No | Proposal | Proposed By | Management Recommendation | Vote Cast |
1 | Approve Financial Statements and Statutory Reports | Management | For | For |
2 | Approve Consolidated Financial Statements and Statutory Reports | Management | For | For |
3 | Approve Allocation of Income and Dividends of EUR 1.16 per Share | Management | For | For |
4 | Non-Binding Vote on Compensation of Henri de Castries, Chairman and CEO until August 31, 2016 | Management | For | For |
5 | Non-Binding Vote on Compensation of Denis Duverne, Vice CEO until August 31, 2016 | Management | For | For |
6 | Non-Binding Vote on Compensation of Denis Duverne, Chairman of the Board of Directors since September 1, 2016 | Management | For | For |
7 | Non-Binding Vote on Compensation of Thoma Buberl, CEO since September 1, 2016 | Management | For | For |
8 | Approve Remuneration Policy of Chairman of the Board | Management | For | For |
9 | Approve Remuneration Policy of CEO | Management | For | For |
10 | Approve Auditors' Special Report on Related-Party Transactions | Management | For | For |
11 | Approve Additional Social Benefits Agreement with Thomas Buberl, CEO | Management | For | For |
12 | Approve Severance Agreement with Thomas Buberl | Management | For | For |
13 | Reelect Deanna Oppenheimer as Director | Management | For | For |
14 | Reelect Ramon de Oliveira as Director | Management | For | For |
15 | Ratify Appointment of Thomas Buberl as Director | Management | For | For |
16 | Ratify Appointment of Andre Francois-Poncet as Director | Management | For | For |
17 | Authorize Repurchase of Up to 10 Percent of Issued Share Capital | Management | For | For |
18 | Authorize Capitalization of Reserves of Up to EUR 1 Billion for Bonus Issue or Increase in Par Value | Management | For | For |
19 | Authorize Issuance of Equity or Equity-Linked Securities with Preemptive Rights up to Aggregate Nominal Amount of EUR 2 Billions | Management | For | For |
20 | Authorize Issuance of Equity or Equity-Linked Securities without Preemptive Rights up to Aggregate Nominal Amount of EUR 550 Million | Management | For | For |
21 | Approve Issuance of Equity or Equity-Linked Securities for Private Placements, up to Aggregate Nominal Amount of EUR 550 Million | Management | For | For |
22 | Authorize Board to Set Issue Price for 10 Percent Per Year of Issued Capital Pursuant to Issue Authority without Preemptive Rights | Management | For | For |
23 | Authorize Capital Increase of Up to EUR 550 Million for Future Exchange Offers | Management | For | For |
24 | Authorize Capital Increase of up to 10 Percent of Issued Capital for Contributions in Kind | Management | For | For |
25 | Authorize Issuance of Equity Upon Conversion of a Subsidiary's Equity-Linked Securities without Preemptive Rights for Up to EUR 550 Million | Management | For | For |
26 | Authorize Issuance of Equity Upon Conversion of a Subsidiary's Equity-Linked Securities with Preemptive Rights for Up to EUR 2 Billion | Management | For | For |
27 | Authorize Capital Issuances for Use in Employee Stock Purchase Plans | Management | For | For |
28 | Authorize Capital Issuances for Use in Employee Stock Purchase Plans Reserved for Employees of International Subsidiaries | Management | For | For |
29 | Authorize up to 1 Percent of Issued Capital for Use in Stock Option Plans | Management | For | For |
30 | Authorize Decrease in Share Capital via Cancellation of Repurchased Shares | Management | For | For |
31 | Authorize Filing of Required Documents/Other Formalities | Management | For | For |